Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018106645) β-1,6-GLUCAN THERAPEUTIC ANTIBODY CONJUGATES
Latest bibliographic data on file with the International BureauSubmit observation

Pub. No.: WO/2018/106645 International Application No.: PCT/US2017/064631
Publication Date: 14.06.2018 International Filing Date: 05.12.2017
IPC:
A61K 39/395 (2006.01) ,A61K 47/61 (2017.01) ,A61P 35/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
[IPC code unknown for A61K 47/61]
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
INNATE BIOTHERAPEUTICS, LLC [US/US]; 16 Everett Street Newton, MA 02459, US
Inventors:
REZNIK, Gabriel, Oscar; US
KANE, John, James; US
SIEDLECKI, James, Michael; US
DOSTALOVA, Zuzana; US
SANSAL-CASTELLANO, Isabelle; US
RUBIN-BEJERANO, Ifat; US
MIAO, Hua; US
FURFINE, Eric, Steven; US
Agent:
ABELLEIRA, Susan, M.; US
Priority Data:
62/431,36207.12.2016US
Title (EN) β-1,6-GLUCAN THERAPEUTIC ANTIBODY CONJUGATES
(FR) CONJUGUÉS D'ANTICORPS THÉRAPEUTIQUE DE β-1,6-GLUCANE
Abstract:
(EN) The present invention encompasses embodiments in which a therapeutic antibody is conjugated to β-1,6-glucan oligomers. Thus, the present invention includes, among other things, compositions including a therapeutic antibody conjugated to one or more β-1-,6-glucan oligomers. The present invention further includes, among other things, methods of making and/or using such β-1,6-glucan conjugates. In certain embodiments, a β-1,6-glucan conjugate of the present invention is useful as a therapeutic or in a method of therapy.
(FR) La présente invention concerne des modes de réalisation dans lesquels un anticorps thérapeutique est conujugué à des oligomères de β-1,6-glucane. Ainsi, la présente invention comprend, entre autres, des compositions comprenant un anticorps thérapeutique conjugué à un ou plusieurs oligomère(s) de β-1,6-glucane. La présente invention comprend également, entre autres, des méthodes permettant de fabriquer et/ou d'utiliser lesdits conjugués de β-1,6-glucane. Dans certains modes de réalisation, un conjugué de β-1,6-glucane de la présente invention est utilisable en tant qu'agent thérapeutique ou au sein d'une méthode de traitement.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)